The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
Abstract
BACKGROUND: The enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT) esterifies cholesterol in a variety of tissues. In some animal models, ACAT inhibitors have antiatherosclerotic effects. METHODS: We performed intravascular ultrasonography in 408 patients with angiographically documented coronary disease. All patients received usual care for secondary prevention, including statins, if indicated. Patients were randomly assigned to receive the ACAT inhibitor pactimibe (100 mg per day) or matching placebo. Ultrasonography was repeated after 18 months to measure the progression of atherosclerosis. RESULTS: The primary efficacy variable analyzing the progression of atherosclerosis--the change in percent atheroma volume--was similar in the pactimibe and placebo groups (0.69 percent and 0.59 percent, respectively; P=0.77). However, both secondary efficacy variables assessed by means of intravascular ultrasonography showed unfavorable effects of pactimibe treatment. As compared with baseline values, the normalized total atheroma volume showed significant regression in the placebo group (-5.6 mm3, P=0.001) but not in the pactimibe group (-1.3 mm3, P=0.39; P=0.03 for the comparison between groups). The atheroma volume in the most diseased 10-mm subsegment regressed by 3.2 mm3 in the placebo group, as compared with a decrease of 1.3 mm3 in the pactimibe group (P=0.01). The combined incidence of adverse cardiovascular outcomes was similar in the two groups (P=0.53). CONCLUSIONS: For patients with coronary disease, treatment with an ACAT inhibitor did not improve the primary efficacy variable (percent atheroma volume) and adversely affected two major secondary efficacy measures assessed by intravascular ultrasonography. ACAT inhibition is not an effective strategy for limiting atherosclerosis and may promote atherogenesis. (ClinicalTrials.gov number, NCT00268515.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Self-citationMintz, G. S., Nissen, S. E., Anderson, W. D., Bailey, S. R., Erbel, R., Fitzgerald, P. J., Pinto, F. J., Rosenfield, K., Siegel, R. J., Tuzcu, E. M., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01175-5 · Cited by 2,185
Self-citationNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Self-citationStatin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Self-citationEisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Self-citationNissen, S. E., Tuzcu, E. M., Libby, P., Thompson, P. D., Ghali, M., Garza, D., Berman, L., Shi, H., Buebendorf, E., Topol, E. J., et al. (2004) · JAMA · doi:10.1001/jama.292.18.2217 · Cited by 1,154
Self-citationConsequences of cellular cholesterol accumulation: basic concepts and physiological implications
Tabas, I. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16452 · Cited by 598
Consequences of cellular cholesterol accumulation: basic concepts and physiological implications
Tabas, I. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216452 · Cited by 540
Libby, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.006 · Cited by 388
ACAT-2, A Second Mammalian Acyl-CoA:Cholesterol Acyltransferase
Cases, S., Novak, S., Zheng, Y.-W., Myers, H. M., Lear, S. R., Sande, E., Welch, C. B., Lusis, A. J., Spencer, T. A., Krause, B. R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26755 · Cited by 344
Cited by
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationEffect of Two Intensive Statin Regimens on Progression of Coronary Disease
Nicholls, S. J., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., Borgman, M., Wolski, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110874 · Cited by 890
Self-citationNissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Self-citationStatins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Self-citationExtended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M., Weissman, N. J., & Turco, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 644
Lipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression
Puri, R., Nicholls, S. J., Shao, M., Kataoka, Y., Uno, K., Kapadia, S. R., Tuzcu, E. M., & Nissen, S. E. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.036 · Cited by 571
Self-citationSerruys, P. W., García-García, H. M., Buszman, P., Erne, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, O., Dudek, D., Bøtker, H. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.771899 · Cited by 505
Self-citationNicholls, S. J., Hsu, A., Wolski, K., Hu, B., Bayturan, O., Lavoie, A., Uno, K., Tuzcu, E. M., & Nissen, S. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.026 · Cited by 475
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Acyl‐coenzyme A:cholesterol acyltransferases
Chang, T.-Y., Li, B.-L., Chang, C. C. Y., & Urano, Y. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90926.2008 · Cited by 443
Nissen, S. E., Nicholls, S. J., Wolski, K., Rodés-Cabau, J., Cannon, C. P., Deanfield, J. E., Després, J.-P., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1547 · Cited by 403
Self-citationMcLaren, J. E., Michael, D. R., Ashlin, T. G., & Ramji, D. P. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.04.002 · Cited by 397
Inflammation in atherosclerosis
Taleb, S. (2016) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2016.04.002 · Cited by 375
Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling
Nicholls, S. J., Tuzcu, E. M., Kalidindi, S., Wolski, K., Moon, K.-W., Sipahi, I., Schoenhagen, P., & Nissen, S. E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.051 · Cited by 349
Self-citationMacrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
Chen, R., Zhang, H., Tang, B., Luo, Y., Yang, Y., Zhong, X., Chen, S., Xu, X., Huang, S., & Liu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01840-1 · Cited by 349
Atherosclerotic Plaque Destabilization: Mechanisms, Models, and Therapeutic Strategies
Silvestre-Roig, C., de Winther, M. P., Weber, C., Daemen, M. J., Lutgens, E., & Soehnlein, O. (2014) · Circulation Research · doi:10.1161/circresaha.114.302355 · Cited by 336
Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies
Curcio, C. A. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24882 · Cited by 318
Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks
Li, X.-M., Tang, W. H. W., Mosior, M. K., Huang, Y., Wu, Y., Matter, W., Gao, V., Schmitt, D., DiDonato, J. A., Fisher, E. A., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301373 · Cited by 301
Macrophage Migration Inhibitory Factor in Cardiovascular Disease
Zernecke, A., Bernhagen, J., & Weber, C. (2008) · Circulation · doi:10.1161/circulationaha.107.729125 · Cited by 280
SCHRIJVERS, D., DEMEYER, G., HERMAN, A., & MARTINET, W. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.005 · Cited by 277
de Groot, E., van Leuven, S. I., Duivenvoorden, R., Meuwese, M. C., Akdim, F., Bots, M. L., & Kastelein, J. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1163 · Cited by 260
Bayturan, O., Kapadia, S., Nicholls, S. J., Tuzcu, E. M., Shao, M., Uno, K., Shreevatsa, A., Lavoie, A. J., Wolski, K., Schoenhagen, P., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.050 · Cited by 174
Self-citationPCSK9 as a therapeutic target of dyslipidemia
Seidah, N. G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802600715 · Cited by 110
Peripheral Arterial Disease and Progression of Coronary Atherosclerosis
Hussein, A. A., Uno, K., Wolski, K., Kapadia, S., Schoenhagen, P., Tuzcu, E. M., Nissen, S. E., & Nicholls, S. J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.034 · Cited by 108
Self-citationStructural basis for catalysis and substrate specificity of human ACAT1
Qian, H., Zhao, X., Yan, R., Yao, X., Gao, S., Sun, X., Du, X., Yang, H., Wong, C. C. L., & Yan, N. (2020) · Nature · doi:10.1038/s41586-020-2290-0 · Cited by 108
Elshazly, M. B., Mani, P., Nissen, S., Brennan, D. M., Clark, D., Martin, S., Jones, S. R., Quispe, R., Donnellan, E., Nicholls, S. J., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319887578 · Cited by 103
Self-citationStructure of nevanimibe-bound tetrameric human ACAT1
Long, T., Sun, Y., Hassan, A., Qi, X., & Li, X. (2020) · Nature · doi:10.1038/s41586-020-2295-8 · Cited by 97
Acat1 Knockdown Gene Therapy Decreases Amyloid-β in a Mouse Model of Alzheimer's Disease
Murphy, S. R., Chang, C. C., Dogbevia, G., Bryleva, E. Y., Bowen, Z., Hasan, M. T., & Chang, T.-Y. (2013) · Molecular Therapy · doi:10.1038/mt.2013.118 · Cited by 96
Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
Crouse, J. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600012-jlr200 · Cited by 66
The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases
Feringa, F. M., Koppes-den Hertog, S. J., Wang, L. Y., Derks, R. J. E., Kruijff, I., Erlebach, L., Heijneman, J., Miramontes, R., Pömpner, N., Blomberg, N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01365-z · Cited by 56
Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., et al. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.01.01 · Cited by 53
Self-citationBlocking cholesterol storage to treat Alzheimer's disease
Chang, T. Y., Chang, C. C. Y., Harned, T. C., De La Torre, A. L., Lee, J., Huynh, T. N., & Gow, J. G. (2021) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2021.00014 · Cited by 28
ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease
Alavez-Rubio, J. S., & Juarez-Cedillo, T. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190823125245 · Cited by 12
Metadata
- Authors
- Nissen, S. E., Tuzcu, E. M., Brewer, H. B., Sipahi, I., Nicholls, S. J., Ganz, P., Schoenhagen, P., Waters, D. D., Pepine, C. J., Crowe, T. D., Davidson, M. H., Deanfield, J. E., Wisniewski, L. M., Hanyok, J. J., & Kassalow, L. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1253-1263
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2107948144
- Cited by
- 398
- References
- 34
- FWCI
- 41.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.